CAJ | 학술논문

目的：分析比较培美曲塞与吉西他滨联合卡铂一线治疗晚期非小细胞肺癌的临床疗效和不良反应，探讨方案的可行性。方法收集我院新院（2011年5月～2012年11月）收治的晚期经病理学证实的非小细胞肺癌患者37例，按治疗方案随机分为两组：A组19例，采用培美曲塞联合卡铂方案；B组18例，采用吉西他滨联合卡铂方案。化疗3周后进行疗效评价及不良反应评价。结果（1）A组ORR及DCR与B组比较差别不大，两组差异无统计学意义（P＞0.05）。（2）A组PFS高于B组，差异有统计学意义（P＜0.05）。1年总生存率与B组比较差异无统计学意义（P＞0.05）。（3）A组副反应发生率低于B组，两组差异有统计学意义（P＜0.05）。结论培美曲塞联合卡铂一线治疗晚期非小细胞肺癌的疗效与吉西他滨联合卡铂的疗效相近，且耐受性较好，患者依从性明显提高，可以推广应用于临床。
목적：분석비교배미곡새여길서타빈연합잡박일선치료만기비소세포폐암적림상료효화불량반응，탐토방안적가행성。방법수집아원신원（2011년5월～2012년11월）수치적만기경병이학증실적비소세포폐암환자37례，안치료방안수궤분위량조：A조19례，채용배미곡새연합잡박방안；B조18례，채용길서타빈연합잡박방안。화료3주후진행료효평개급불량반응평개。결과（1）A조ORR급DCR여B조비교차별불대，량조차이무통계학의의（P＞0.05）。（2）A조PFS고우B조，차이유통계학의의（P＜0.05）。1년총생존솔여B조비교차이무통계학의의（P＞0.05）。（3）A조부반응발생솔저우B조，량조차이유통계학의의（P＜0.05）。결론배미곡새연합잡박일선치료만기비소세포폐암적료효여길서타빈연합잡박적료효상근，차내수성교호，환자의종성명현제고，가이추엄응용우림상。
Objective To compare the clinical efficacy and adverse reactions of the pemetrexed and gemcitabine compared with carboplatin in first-line treatment of advanced non-small cell lung cancer,and explore the feasibility of the program. Methods 37 cases of histologically confirmed advanced non-small cell lung cancer patients were selected from the new hospital(from May 2011 to November 2012),they were randomly divided into two groups according to the treatment plan: group A included 19 cases,they used pemetrexed and carboplatin; group B included 18 cases, they used gemcitabine and carboplatin. The efficacy and adverse reactions of chemotherapy were evaluated after three weeks. Results (1)There were no significant difference in ORR and DCR between group A and group B(P > 0.05).(2)PFS of group A was higher than group B, the difference was significant(P < 0.05).There were no significant difference in 1-year overall survival between group A and group B(P > 0.05).(3)The side effects rate of group A was lower than group B,the difference was significant(P < 0.05). Conclusion The efficacy of pemetrexed and carboplatin in first-line treatment of advanced non-small cell lung cancer and efficacy of gemcitabine and carboplatin are similar,and well tolerated,can significantly improve patient's compliance and can be extended to the clinic.